济南痛风怎样检查才知道是痛风济南初期痛风症状图片,山东体检前大量喝水能降低尿酸吗,济南痛风是啥原因,山东怎么治疗脚趾痛风,济南血尿酸高如何降下来,济南痛风石有危险吗,山东痛风禁吃哪些食物

BEIJING, Feb. 26 (Xinhua) -- China's Ministry of Education said Friday that 34.29 million students graduated from the country's higher-learning institutions between 2006 and 2010.Xu Mei, the ministry's spokeswoman, said the number is even more than that of the graduates in the 20 years prior to 2006 combined."During the 11th five-year plan period (2006-2010), higher education has become even more accessible to the general public. Higher-learning institutions provide a strong support of brain power and human resources to the social and economic development," Xu said.The "Outline of China's National Plan for Medium and Long-Term Education Reform and Development (2010-2020)," which was publicized last year, says "the strategic goals to be attained by 2020 are to basically modernize education; shape a learning society; and turn China into a country rich in human resources."

BEIJING, Feb. 22 (Xinhua) -- Chinese Foreign Minster Yang Jiechi and his Austrian counterpart Michael Spindelegger held talks here on Tuesday, pledging to enhance bilateral ties through deeper cooperation.Yang hailed the remarkable development of bilateral ties since the two countries established diplomatic relations 40 years ago.He said both sides should see the 40th anniversary as a new starting point for maintaining traditional friendship, deepening political mutual trust, expanding cooperation and enhancing cultural exchanges, to strive for greater development of bilateral ties.He stressed that China appreciates the Austrian government's adherence to the one-China policy.For his part, Spindelegger said the Austrian side attaches great importance to developing ties with China and he hoped both sides will strengthen cooperation in various fields in a more pragmatic way.The two also exchanged views on some international and regional issues of common concern.

CHICAGO, Jan. 21 (Xinhua) -- Chinese President Hu Jintao left Chicago for China on Friday after concluding a state visit to the United States, during which he and his U.S. counterpart Barack Obama agreed to build a China-U.S. cooperative partnership based on mutual respect and mutual benefit.Hu, who began his four-day visit Tuesday, had extensive and in-depth discussions with Obama at the White House on Wednesday on major bilateral, regional and world issues.Chinese President Hu Jintao shakes hands with U.S. President Barack Obama during a bilateral meeting at the White House in Washington, the United States, Jan. 19, 2011.The two sides reached "important agreement on China-U.S. relations and major international and regional issues of shared interests," the Chinese president said when he and Obama met the press following their discussions."We both agree to further push forward the positive, cooperative and comprehensive China-U.S. relationship," Hu said, adding that both sides also pledged to forge "a China-U.S. cooperative partnership based on mutual respect and mutual benefit" for the benefit of the two countries and beyond.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.